Literature DB >> 10498451

Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.

P Rutgeerts.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498451      PMCID: PMC1727559          DOI: 10.1136/gut.45.1.13

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  1 in total

1.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.